
Aadrikaa Legal Services (ALS) – IDT Tax I Arbitration I Litigation
Date: 05.05.2026
Supreme Court Ruled on Classification, Valuation, and Limitation of Ayurvedic Medicaments under Central Excise Law

This Short Article has been prepared & written by Advocate Ravi Shekhar Jha-Delhi High Court, New Delhi. The views expressed are based on his interpretation of the law. He can be reached at his email id intelconsul@gmail.com .
The Supreme Court of India delivered a landmark judgment in the case of Commissioner of Central Excise, Delhi vs. Ishaan Research Lab (P) Ltd. & Others, addressing crucial issues of classification, valuation, and limitation under Central Excise law. This article provides a detailed overview of the case, its background, the legal arguments, and the final verdict, offering insights into how Ayurvedic products are treated under Indian excise regulations.
Case Background
- Parties Involved: Commissioner of Central Excise, Delhi (Appellant) vs. Ishaan Research Lab (P) Ltd. & Others (Respondents)
- Appeals Disposed: Civil Appeal Nos. 7357-7372 of 2001 and Civil Appeal No. 2517 of 2002
- Period Covered: April 1991 to June 1997
- Key Issue: Whether 22 products manufactured by Ishaan Research Lab should be classified as “Ayurvedic medicines” (Chapter 30, Entry 3003.30) or as “cosmetics/toilet preparations” (Chapter 33) under the Central Excise Tariff.
Legal Issues Examined
1. Classification of Products
- Revenue’s Argument: The products were cosmetics/toilet preparations, attracting a higher excise duty (40% ad valorem).
- Assessee’s Argument: The products were Ayurvedic medicines, eligible for a lower duty (10% ad valorem).
- Tribunal’s Finding: 22 products were classified as Ayurvedic medicines under Chapter 30, Entry 3003.30.
- Supreme Court’s Analysis:
- Examined product ingredients, manufacturing licenses, and product labels.
- Relied on precedents such as BPL Pharmaceuticals Ltd. v. Collector of Central Excise and Sharma Chemical Works v. Commissioner of Central Excise.
- Noted that products manufactured under a drug license and containing Ayurvedic medicinal herbs, with labels claiming medicinal properties, should be classified as medicaments, not cosmetics.
- The “common parlance test” is not the sole criterion; expert opinions and regulatory compliance are also crucial.
2. Valuation of Products
- Tribunal’s Finding: IRLP and its marketing entities were not “related persons” under Section 4(4)(c) of the Central Excise Act.
- Supreme Court’s Decision:
- Where IRLP sold products to both IMPL and independent third parties, the lowest price charged to third parties should be used for valuation.
- Where products were only sold to IMPL, the wholesale price charged by IMPL to dealers should be used.
- Permissible deductions (discounts, freight, excise duty, sales tax) should be allowed as per law.
3. Limitation Period
- Revenue’s Argument: Sought to apply the extended period of limitation for duty recovery.
- Tribunal’s Finding: Extended period not applicable; normal limitation period of six months applies.
- Supreme Court’s Decision: Affirmed Tribunal’s finding, referencing the Allahabad High Court’s decision in Shahnaz Ayurvedics and noting no suppression or misstatement by the assessee.
Key Products in Dispute
The judgment focused on 16 products, including:
- Bio Aloevera
- Bio Bhringraj
- Bio-cucumber
- Bio-coconut
- Bio-costus
- Bio-kelp
- Bio-milk
- Bio-margosa
- Bio-peach
- Bio-pro
- Bio-quince
- Bio-saffron
- Bio-soya
- Bio-wheat
- Bio-wintergreen
- Bio-walnut
Precedents and Legal Principles
- Medicaments vs. Cosmetics: The court clarified that products with medicinal value, manufactured under a drug license, and marketed as such, should be classified as medicaments even if they have beautification effects.
- Common Parlance Test: While relevant, it is not decisive; regulatory and expert evidence is more important.
- Burden of Proof: The onus is on the Revenue to prove a product is a cosmetic if it seeks higher duty.
Final Verdict
- The Supreme Court dismissed the appeals of the Revenue, affirming the Tribunal’s classification of the products as Ayurvedic medicines.
- The valuation method and limitation period as decided by the Tribunal were upheld.
- No costs were imposed due to the circumstances of the case.
Significance
This judgment sets a clear precedent for the classification of Ayurvedic products under Central Excise law, emphasizing the importance of manufacturing licenses, product labels, and expert opinions over mere market perception. It also clarifies valuation and limitation principles, providing guidance for similar disputes in the future.
Source: Supreme Court
Handy Download:
Write to us at office@aadrikaalaw.com
Tel: +91-11-4999 2707 I +91-9999005379





